|Bid||86.34 x 800|
|Ask||334.82 x 800|
|Day's Range||208.28 - 211.26|
|52 Week Range||171.43 - 263.62|
|Beta (5Y Monthly)||1.12|
|PE Ratio (TTM)||34.41|
|Earnings Date||Apr 26, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||262.14|
Subscribe to Yahoo Finance Plus to view Fair Value for ICLR
When we invest, we're generally looking for stocks that outperform the market average. And while active stock picking...
DUBLIN, March 29, 2023--ICON plc Schedules First Quarter 2023 Earnings Conference Call
According to the National Center for Advancing Translational Sciences, the average period from therapy discovery to Food and Drug Administration (FDA) approval is 14 years and costs $1 billion. Clinical research organizations (CROs) and contract development and manufacturing organizations (CDMOs) are growing because the increasing price of developing, testing, manufacturing, and marketing therapies has made it more important that pharmaceutical companies speed the process along with fewer failures. Rather than doing all the clinical trial work or manufacturing work in-house, more healthcare companies are turning to CROs and CDMOs to reduce overhead and expedite bringing therapies to market.